|Bid||5.94 x 1100|
|Ask||5.95 x 1300|
|Day's Range||5.83 - 6.03|
|52 Week Range||2.23 - 9.09|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||3.86|
|Earnings Date||May 10, 2021 - May 14, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Nov 04, 2015|
|1y Target Est||8.00|
Arix Bioscience, the biotechnology investor backed by restaurant tycoon Richard Caring and biotech entrepreneur Sir Christopher Evans, has been forced to halt two board appointments after its largest shareholder called for a total overhaul in a scathing letter. Mayfair-based Arix has had to pause the planned hire of two directors due to join the business this month after Acacia Research, an American investor advised by Neil Woodford, said in a damning public letter that the firm faced “seemingly uncontrollable board tumult” and was being led by a “woefully inadequate investment group” after 18 director departures in five years. In response, Arix said it had an experienced board and was already building its investment team in the UK and the US. Fallen fund manager Mr Woodford is not advising Acacia on this saga, people familiar with the matter said. Arix was due to welcome Dr Axel Wieandt, a former Morgan Stanley and Deutsche Bank banker, on to the board alongside biotech expert James Noble. However it has told investors that while the pair remain “highly qualified” the appointments are on hold while it reviews parts of the business including “the question of board composition”.
Acacia Research Corporation (Nasdaq: ACTG) today reported results for the three and 12-month period ended December 31, 2020.
Acacia Research Corporation ("Acacia" or "the Company") (NASDAQ: ACTG) announced today it will release its fourth quarter and year-end 2020 financial results on Monday, March 29, 2021 at 8:00 a.m. ET/ 5:00 a.m. PT.